>
Switch to:

Travere Therapeutics Capex-to-Revenue

: 2.04 (As of Dec. 2020)
View and export this data going back to 2003. Start your Free Trial

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Travere Therapeutics's Capital Expenditure for the three months ended in Dec. 2020 was $-103.88 Mil. Its Revenue for the three months ended in Dec. 2020 was $50.98 Mil.

Hence, Travere Therapeutics's Capex-to-Revenue for the three months ended in Dec. 2020 was 2.04.


Travere Therapeutics Capex-to-Revenue Historical Data

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Travere Therapeutics Annual Data
Feb11 Feb12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Capex-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.09 0.12 0.09 0.60

Travere Therapeutics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Capex-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.10 0.09 0.14 2.04

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Travere Therapeutics Capex-to-Revenue Distribution

* The bar in red indicates where Travere Therapeutics's Capex-to-Revenue falls into.



Travere Therapeutics Capex-to-Revenue Calculation

Travere Therapeutics's Capex-to-Revenue for the fiscal year that ended in Dec. 2020 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-119.845) / 198.321
=0.60

Travere Therapeutics's Capex-to-Revenue for the quarter that ended in Dec. 2020 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-103.88) / 50.983
=2.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Travere Therapeutics  (NAS:TVTX) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Rvenue Raio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Travere Therapeutics Capex-to-Revenue Related Terms


Travere Therapeutics Capex-to-Revenue Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)